Skip to content
Menu
CareerMVP
  • Home
  • Search
    • Jobs
    • News
  • Post
    • Nominate
    • Membership
    • Post Jobs
  • Channels
    • BusinessMVP
    • Local Career Sites
    • Trade Publications
    • Local Publications
Close Menu

Zarzio® overtakes Neupogen® and Granocyte® to become most prescribed daily G-CSF in Europe

Health, Medical, Pharmaceuticals, Press Releases

Holzkirchen, Germany, July 22, 2013 – Sandoz, the global leader in biosimilars, is pleased that Zarzio® (filgrastim) has become the first biosimilar to overtake both its reference product (Amgen’s Neupogen®) and European market leader (Chugai’s Granocyte®) and is now the most prescribed daily G-CSF in Europe and the #1 biosimilar daily G-CSF globally.

The success of Zarzio reflects the growing acceptance of biosimilars by stakeholders all over the world and affirms physician confidence in its proven safety and efficacy across oncology settings.

Since Sandoz began marketing Zarzio in 2009 it has been prescribed to more than 100,000 patients worldwide, has generated over 4 million patient exposure days of experience, and is marketed in more than 40 countries.  Importantly, the availability of Zarzio has rapidly expanded patient access to this essential biologic and facilitated overall growth in the use of filgrastim without increasing total costs to healthcare systems.

“The success of Zarzio affirms our biosimilars development approach which utilizes state-of-the-art analytical techniques, robust process development, and tailored clinical programs,” said Ameet Mallik, Sandoz’ Head of Biopharmaceuticals and Oncology Injectables. “Our focus on providing a high-quality product with value-added services at an affordable price has made the difference commercially as well.”

Sandoz is the pioneer and global leader in biosimilars with over 50% share of all biosimilars approved in the highly regulated markets of U.S., Canada, Europe, Japan and Australia. Our three biosimilars – each of which occupies the #1 biosimilar position in their respective categories – are sold in over 50 countries and have generated over 100 million patient exposure days in experience. Sandoz also has an unrivalled pipeline with a total of seven ongoing Phase III trials across five molecules – more than any other company in the industry.

SOURCE: Sandoz

Related Posts

Press Releases

Electric Last Mile Provides Update on Pre-orders and Start of Production

Press Releases

Lion Electric Secures its Largest Truck Order to Date with 100 Zero-Emission Trucks from Pride Group Enterprises

Press Releases

Arrival Lists its Shares on Nasdaq With the Symbol “ARVL”; First Electric Vehicles due Q4 2021

Featured Jobs

  • Material Handler Part-Time PM shift at Rickenbacker Airport $15.08/ hr.

    • Columbus, OH
    • FedEx Express
    • Part Time
  • MGR- OBSERVATION CENTER 8SOUTH

    • Lansing, MI
    • Sparrow Health System
    • Full Time
  • SURG TECHNOLOGIST-CERT

    • Lansing, MI
    • Sparrow Health System
    • Full Time
  • ADM – ORTHOPEDICS 6W

    • Lansing, MI
    • Sparrow Health System
    • Full Time
  • ADM – MEDICAL ICU 10W

    • Lansing, MI
    • Sparrow Health System
    • Full Time
  • SHS-MGR CLINICAL INTEGRATION

    • Lansing, MI
    • Sparrow Health System
    • Full Time
  • Warehouse Worker/ Material Handler- PT-$14.08 an hour plus benefits

    • Great Falls, MT
    • FedEx Express
    • Part Time

Featured News

  • Electric Last Mile Provides Update on Pre-orders and Start of Production
  • Lion Electric Secures its Largest Truck Order to Date with 100 Zero-Emission Trucks from Pride Group Enterprises
  • Arrival Lists its Shares on Nasdaq With the Symbol “ARVL”; First Electric Vehicles due Q4 2021
  • Cummins supplying batteries for Altec’s Jobsite Energy Management System
  • Electric Last Mile and Geotab, Inc. Announce Partnership
Back To Top
CareerMVP
Copyright © BusinessMVP.com
All Rights Reserved!